ZimVie Inc. (ZIMV) entered a merger agreement on July 21, 2025, to be acquired by ARCHIMED in a deal valued at $730 million.
Under the terms of the agreement, ZimVie stockholders will receive $19.00 in cash for each share of ZimVie common stock, representing a premium of 125.12% from the stock’s last close.
ZimVie is a global medical technology company that develops and delivers innovative dental and spine solutions, including implants, biomaterials, digital workflow tools, and spinal fusion and motion preservation technologies, to restore health and quality of life worldwide.
Archimed is a global investment firm specializing in healthcare, with offices across Europe, North America, and Asia, managing around 8 billion euros to support small- and mid-cap companies through strategic growth in areas like MedTech, Biopharma, and Diagnostics.
The deal is expected to close by year-end 2025.
ZimVie also has a 40-day go-shop period expiring on August 29, 2025.
Centerview Partners and Cravath, Swaine & Moore are serving as financial and legal advisors, respectively, to ZimVie, while UBS Investment Bank is providing financial guidance and Latham & Watkins is acting as legal counsel to ARCHIMED.
ARCHIMED is buying ZimVie at 19.60 times its EBITDA.
To gain a deeper insight into this M&A transaction, you are encouraged to visit the Deal Metrics page here:
Deal Metrics for the acquisition of ZimVie Inc. (ZIMV) by ARCHIMED
The Deal Metrics page for each merger or acquisition includes:
Disclaimer: We urge you to conduct your own due diligence before buying or selling any securities mentioned in this article. We do not guarantee the completeness or accuracy of the content or data provided in this article.
Editor’s Note: Baranjot Kaur contributed to this article